casodex 50 mg (pi pharma) filmomh. tabl.
pi pharma sa-nv - bicalutamide 50 mg - filmomhulde tablet - bicalutamide
casodex 50 mg (pi pharma) filmomh. tabl.
pi pharma sa-nv - bicalutamide 50 mg - filmomhulde tablet - bicalutamide
casodex 150 mg (pi pharma) filmomh. tabl.
pi pharma sa-nv - bicalutamide 150 mg - filmomhulde tablet - bicalutamide
casodex 50 mg (pi pharma) filmomh. tabl.
pi pharma sa-nv - bicalutamide 50 mg - filmomhulde tablet - bicalutamide
marcoumar 3 mg tabl.
viatris healthcare sa-nv - fenprocoumon 3 mg - tablet - 3 mg - fenprocoumon 3 mg - phenprocoumon
teceos 13 mg kit voor radiofarmaceutisch preparaat
cis bio international (gif sur yvette) route nationale 306 91192 gif sur yvette cedex (frankrijk) - butedronaat tetranatrium 13 mg/flacon - kit voor radiofarmaceutisch preparaat - n-(4-aminobenzoyl)-l-glutamic acid (ri) ; natriumhydroxide (e 524) ; stannous oxide (ri), - technetium (99m tc) butedronic acid
enzalutamide sandoz 40 mg, zachte capsules
enzalutamide 40 mg/stuk - capsule, zacht - butylhydroxyanisol (e 320) ; butylhydroxytolueen (e 321) ; caprylocaproylmacrogolglyceriden ; gelatine (e 441) ; glycerol (e 422) ; sorbitol vloeibaar, gedeeltelijk gedehydrateerd ; titaandioxide (e 171) ; water, gezuiverd
xtandi
astellas pharma europe b.v. - enzalutamide - prostaatnoplasma - endocriene therapie - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
enzalutamide sandoz 40 mg, filmomhulde tabletten
enzalutamide 40 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; hypromelloseacetaatsuccinaat ; ijzeroxide geel (e 172) ; lactose 1-water ; macrogol 6000 ; magnesiumstearaat (e 470b) ; talk (e 553 b) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; hypromelloseacetaatsuccinaat ; ijzeroxide geel (e 172) ; lactose 1-water ; macrogol 6000 ; magnesiumstearaat (e 470b) ; talk (e 553 b) ; titaandioxide (e 171)
enzalutamide sandoz 80 mg, filmomhulde tabletten
enzalutamide 80 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; hypromelloseacetaatsuccinaat ; ijzeroxide geel (e 172) ; lactose 1-water ; macrogol 6000 ; magnesiumstearaat (e 470b) ; talk (e 553 b) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; hypromelloseacetaatsuccinaat ; ijzeroxide geel (e 172) ; lactose 1-water ; macrogol 6000 ; magnesiumstearaat (e 470b) ; talk (e 553 b) ; titaandioxide (e 171)